维多利亚老品牌76696vic-在线入口

Be the most trusted biotech company

2023-04-06

CDE Grants Breakthrough Therapy Designation to Henlius BRAF Inhibitor HLX208
2023-03-31

Henlius 2022 Annual Results: Significant Achievements in Commercialisation, Surged to RMB3.2 Billion in Revenues
2023-03-23

EMA Validates Marketing Authorization Application for Henlius' HANSIZHUANG (Serplulimab)
2023-03-17

Cell’s trends reviews journal published the regulatory differences of Henlius' biosimilar for approval between Europe and China
2023-03-15

Henlius Novel anti-OX40 HLX51 Received Clinical Trial Approval in China
2023-02-15

Henlius Announces U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar Trastuzumab HLX02
2023-02-10

First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Henlius Bevacizumab for Treatment of Ophthalmic Diseases
2023-02-03

Nature Medicine Published the Results of ASTRUM-007: HANSIZHUANG Combined with Chemotherapy for the First-line Treatment of Esophageal Squamous Cell Carcinoma
2023-02-02

Henlius completed the phase 1b/2 clinical trial of HLX07 for the treatment of advanced solid tumours

1
...
4
5
6
7
8